Median Technologies · EURONEXT:ALMDT
Median Technologies — Cowen and Company 35th Annual Health Care Conference 2015
22 slides from Median Technologies's conference presentation, Mar 4, 2015
Slide 1: From Qualitative Subjective Art to Quantitative Objective Science
From Qualitative Subjective Art to Quantitative Objective Science March 4th , 2015 Cowen and Company 35th Annual Health Care Conference Boston Fredrik Brag Chairman & CEO MEDIAN Technologies www.mediantechnolologies.com
Slide 2: Mission
Mission We are committed to the improvement of patient outcomes through innovation in medical imaging and quality execution to provide better screening, diagnosis and monitoring of cancer patients MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 2
Slide 3: Disclaimer
Disclaimer MEDIAN Technologies, its directors, officers, advisors and employees make no representation or warranty as to statistical data or predictions contained in this presentation that were taken or derived from third party sources or industry publications; such statistical data and forecasts ar
Slide 4: Oncology Imaging Solutions and Services
Oncology Imaging Solutions and Services • Develop software solutions and services for the interpretation and monitoring of oncology imaging and cancer patients SCREENING DIAGNOSIS MONITORING • Standardize and automate the interpretation of medical images in oncology and assess patient response to th
Slide 5: Overview
Overview MEDIAN Technologies Provides Excellence in Medical Imaging • Based in Sophia-Antipolis, France • Subsidiary in US, Boston, MA • Key opinion leaders and medical partners • Global Imaging Solutions with focus in Oncology: – Imaging services for clinical trials: ongoing projects with global To
Slide 6: Part 1: A Disruptive Technology
Part 1 1 A DISRUPTIVE TECHNOLOGY MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 6
Slide 7: Lesion Management Solutions
Lesion Management Solutions Automated and Standardized Image Management LMS automatically detects, quantifies, and tracks lesions Limits reader subjectivity Increases accuracy and reproducibility DETECT Reduces reader variability, 35% variability between 2 readers Monitor patient evolution
Slide 8: A Disruptive Technology
A Disruptive Technology Manage and Share Imaging Data to Monitor Patient Follow up Automatic generation of imaging reports Imaging and patient follow up Database Software Architecture compatible with physical or virtual machines (cloud computing) MEDIAN Technologies – Tel : +33 493 333 777 – i
Slide 9: LMS Overview – System Demo
LMS Overview – System Demo MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 9
Slide 10: Part 2: Business Development
Part 2 1 BUSINESS DEVELOPMENT MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 10
Slide 11: Sales Strategy
Sales Strategy TARGET MARKETS CLINICAL TRIALS PATIENT CARE • Biopharma companies • Government Healthcare MARKET PLAYERS Authorities & Agencies, • CRO’s • Hospitals, clinics, radiology • iCRO’s facilities, screening centers, oncology centers FOCUSED MARKET SELECTED NATIONAL MARKETS SALES STRATEGY • D
Slide 12: Clinical Trial Market
Clinical Trial Market The stakes are very important – It costs $1.3Bn*** to bring a new cancer drug to market – Strong pressure from payer organization to demonstrate drug efficacy Clinical Trials: $82Bn* Target Market: $1.2Bn/year Oncology Trials: $31Bn** Strong Growth in the Market: +14% per year*
Slide 13: Patient Care Market
Patient Care Market Size & Market trends* What is at stake • 14.1 million new cancer cases per year and • Imaging is a key marker for the screening, diagnosis 32.6 million living with cancer and monitoring of cancer patients • According to WHO, cancer mortality will • Treatment costs per patient can
Slide 14: Business Model: Software as a Service (SaaS)
Business Model: Software as a Service (SaaS) SaaS model, fee per patient, cloud computing solutions or integrated on sites for: • Clinical Trial Market: – Charging between €150K to €1.8M depending on the number of patients – Recurring business, big Pharma are spending between $20-60M per year for im
Slide 15: Part 3: Market Penetration 2014 – 2015
Part 3 1 MARKET PENETRATION 2014 – 2015 • Clinical Trials • Patient Care • R&D Strategy MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 15
Slide 16: Clinical Trial Market Strategy
Clinical Trial Market Strategy PARTNERSHIPS REFERENCING RECURRING MOVING UP THE GEOGRAPHY BUSINESS LADDER Strategic New project New contracts Become the Wider Alliances awards with big with existing natural incumbent international pharma customers for new clinical reach through its trial phases part
Slide 17: Clinical Trial Market Commercial Ramp Up
Clinical Trial Market Commercial Ramp Up €11M ORDER BOOK €7,3M 6,8 €5,8M €4,7M 3,7 €3,9M €2,9M 3,2 3,4 2,9 4,2 2,3 3,6 2,6 1,0 1,3 0,6 0,6 H1 2012 H1 2013 9 months 2013 2013 H1 2014 9 months 2014 2014 Project award * * A project award is a notification announcing that the company's solution has been
Slide 18: Patient Care: Target Markets
Patient Care: Target Markets INITIAL MATURING BLUE SKY OPPORTUNITIES MARKETS MARKETS LUNG CANCER INITIAL BIG DATA REGION-WIDE SCREENING ASSESSMENT at for LUNG CANCERS SCREENING REGION-LEVEL to PHARMA/PAYERS PROGRAMS COUNTRY-WIDE INITIAL BIG DATA DIAGNOSIS & REGION-WIDE ASSESSMENT at for MANY CANCERS
Slide 19: Patient Care: targeting Health Authorities
Patient Care: targeting Health Authorities LMS LMS UNIQUE SAAS USERS UNIQUE SAAS IMAGING SCREENING, USERS DIAGNOSIS & BIOPHARMA PLATFORM COMPANIES MONITORING INVESTIGATOR 1) Automated SOLUTION SITES lesion quantification HEALTH 1) Guide and 2) Automated AUTHORITIES monitor all sites lesion RADIOLOGI
Slide 20: R&D Strategy
R&D Strategy • Implement a commercial Cloud Computing Offering • Apply the MEDIAN imaging technology to new therapeutic indications – in Neurology (Alzheimer’s, Multiple Sclerosis, Parkinson, etc..) and – in Cardiology • Develop novel imaging biomarkers as companion tests for new cancer drugs • Scre
Slide 21: Key Take-Away
Key Take-Away MARKET DRIVERS Addressable Pharma market is Improve quality outcome & clinical $1.2Bn per year decision making Patient care market (screening Reduce costs & duration of trials programs, patient diagnosis and Reduce lung cancer mortality rate monitoring) offers huge untapped t
Slide 22: MEDIAN, an opportunity to differentiate and add value
MEDIAN, an opportunity to differentiate and add value “We are all looking for new and different ways to stand out and stay ahead of the crowd.” MEDIAN Technologies – Tel : +33 493 333 777 – info@mediantechnologies.com - March 2015 22
MEDIAN Technologies — Cowen and Company 35th Annual Health Care Conference 2015 on 6ix